Colon cancer is the third most prevalent form of cancer in the U.S., and while screening has helped detect and prevent colon ...

The addition of postsurgical atezolizumab immunotherapy to standard-of-care chemotherapy in patients with stage III deficient ...

Colon cancer is the third most prevalent form of cancer in the U.S., and while screening has helped detect and prevent colon ...

The risk of recurrence or death after surgery for deficient mismatch repair (dMMR) colon cancer decreased by 50% in patients ...

Adding immunotherapy to chemotherapy after surgery for stage 3 colon cancer may help decrease recurrence and death rate by 50 ...

Adding Roche's immunotherapy drug Tecentriq to chemotherapy after surgery in certain patients whose colon cancer had spread ...

Drugs that boost the body’s immune system to fight disease are showing promise in treating a variety of cancers in earlier ...

Colon cancer is the third most prevalent form of cancer in the U.S., and while screening has helped detect and prevent colon ...

Adding atezolizumab to chemo in stage 3 dMMR colon cancer halves the risk of recurrence, marking a major step in precision ...

Tecentriq and chemotherapy combination reduces the risk of death versus chemotherapy alone in deficient mismatch repair, ...